Navigation Links
Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
Date:6/2/2009

SFARI Base to Usher in 'New Paradigm of Research Collaboration'

NEW HAVEN, Conn., June 2 /PRNewswire/ -- Prometheus Research has signed a three year contract with the New York-based Simons Foundation to expand their development partnership on SFARI Base, the HTSQL-based informatics platform that helps researchers collaborate on understanding the causes of autism. The collaboration is part of the Simons Foundation Autism Research Initiative (SFARI).

Prometheus, a database management software company headquartered here, created the groundbreaking HTSQL platform, which allows for real-time access and configuration of databases via the web. Their flagship product for the biomedical research market, RexDB(R), formed the basis for SFARI Base, and is already used by over a dozen leading research universities, such as Harvard, Yale, Columbia, and the University of California - Los Angeles.

"Prometheus Research and its HTSQL web-based database software are enabling researchers to usher in a new paradigm of research collaboration with SFARI Base," said Stephen B. Johnson PhD, Associate Professor, Biomedical Informatics, Columbia University, working with the Simons Foundation. "This web-based tool offers researchers unprecedented access to DNA specimens on affected families, combined with high quality phenotype data," Johnson said.

The SFARI mission is to improve the diagnosis, treatment, and prevention of autism and related developmental disorders. The SFARI database, known as SFARI Base, is a new resource for autism research that provides the scientific community access to genetic and phenotypic information on 2000 families.

"Researchers need flexible, adaptive, and secure informatics systems that empower them to uncover critical data easily, from wherever they are, over the web," said Leon Rozenblit, president, Prometheus Resear
'/>"/>

SOURCE Prometheus Research
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prometheus Licenses COLAL-PRED(R) From Alizyme
2. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
3. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... WALTHAM, Mass., Nov. 19 Arlington...nd that the leading driver of antibiotic selection...um activity against gram-positive and gram-negativ...can cause nosocomial pneumonia, surveyed European ...nts that provide appropriate coverage against comm...
(Date:11/19/2009)...RNewswire/ - Aegera Therapeutics Inc. announced to...d Phase 2B study of AEG35156, a targeted antisense... oncology indications. ,, The study, entitled "...nked Inhibitor of Apoptosis (XIAP) Antisense AEG35... and Idarubicin in AML Following Failure of a Sing...
(Date:11/19/2009)...,s Top Gene Synthesis Companies Form International...st Practices in Risk Reduction ,Five Member Comp...esis Capacity , (PRWEB) N...ing gene synthesis companies today announced agree...col to promote biosecurity in the gene synthesis i...
(Date:11/19/2009)...ria, November 19 AFFiRiS AG will f...t candidate at an unexpectedly early,stage of deve...enter into,Phase II clinical trial early in 2010. ...he completion of two Phase I trials with the candi...cision on the first interim,analysis of the second...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...th Systems, Inc. (Nasdaq: DCTH ), a medical tec...us Hepatic Perfusion ("PHP") System for the treatm...the first fifty percent (46 of 92) of patients hav...eating metastatic cutaneous and ocular melanoma to...rs in this trial continue to evaluate and enroll p...
...1 , - SCRIP Awards Recognises the Best and Brig...stries Worldwide, - Glenmark is the Only Indian...ecognition, , The best and brightest of the ...ted at a glittering ceremony in London at the 2008... Peter Sissons on December 10th. At this award,cer...
...iate Action to Protect and Maximize Shareholder Va... Fund, L.P., the owner, together with its affiliat...mon stock of Avigen, Inc. (Nasdaq: AVGN ) announ...,s Board of Directors expressing its displeasure w...ruction of shareholder value. , , The text ...
Other Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5
(Date:11/19/2009)...an 2: The offspring of two inbred strains tend to ...ng the gene-level variability that leads to this p...ld boost our ability to custom-tailor crops for sp...man consumption or high glucose content for biomas... sequence of the common corn strain B73, Universit...
(Date:11/19/2009)...t Louisiana Tech University has found that a natur...bicide against giant salvinia. , Giant salvinia ...ock all sunlight penetration into bodies of water,...ns, it,s been reported that giant salvinia can dou...er, professor of biological sciences at Louisiana ...
(Date:11/19/2009)...s identified thousands of diverse genes in genetic...niques may allow breeders and researchers to use t... and create new varieties that were not easily pos...of Science , the researchers, whose senior and fi...st map of haplotypes sets of closely linked gene ...
Breaking Biology News(10 mins):U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Microorganism may provide key to combating giant salvinia throughout Louisiana 2New map of variation in maize genetics holds promise for developing new varieties 2H1N1 Swine Flu Leads to Cancellation of HIV AIDS Summer Camp One Heartland Announces Campaign to Fund Alternative Camp Session for 82 Children 52777 1H1N1 Swine Flu Leads to Cancellation of HIV AIDS Summer Camp One Heartland Announces Campaign to Fund Alternative Camp Session for 82 Children 52777 2Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 1Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 2Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 1Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 2Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 3
...ous mechanism used by a particular enzyme to modif...come a step closer to designing a new kind of drug...their tracks. Their research will be published in ...have known for many years that an enzyme called Da...regulating gene expression in many bacteria. Each ...
...um that can survive encounters with specific immun... that these plentiful white blood cells, known as ...l permit or prevent bacterial infections. A paper ...in The Journal of Immunology. Frank R. DeLeo, Ph.D...he National Institute of Allergy and Infectious Di...
...embryonic stem cell research receives a tremendous...lso exploring the potential of adult stem cells fo...difficulties. Although adult stem cell research is...mbryonic stem cells, adult stem cells are extremel...ab dish. Now, as reported in the May 6 issue of th...
Other Biology News:Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3Researchers discover mechanism for multiplying adult stem cells 2
Macrophage Differentiation Kit from 3H Biomedical AB
Goat Anti-HAS1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Frozen Tissue Section Panel - Monkey (Rhesus) Normal Tissue, Multi-tissue I from BioChain
Frozen Tissue Section Panel - Monkey (Cynomolgus) Normal Tissue, Multi-tissue I from BioChain
Biology Products: